IN8bio (INAB) Competitors $0.33 -0.04 (-10.76%) (As of 11:42 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INAB vs. RLMD, ANVS, ORMP, GNLX, AVTX, TLSA, ALGS, GNTA, NVCT, and ELYMShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Relmada Therapeutics (RLMD), Annovis Bio (ANVS), Oramed Pharmaceuticals (ORMP), Genelux (GNLX), Avalo Therapeutics (AVTX), Tiziana Life Sciences (TLSA), Aligos Therapeutics (ALGS), Genenta Science (GNTA), Nuvectis Pharma (NVCT), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Relmada Therapeutics Annovis Bio Oramed Pharmaceuticals Genelux Avalo Therapeutics Tiziana Life Sciences Aligos Therapeutics Genenta Science Nuvectis Pharma Eliem Therapeutics IN8bio (NASDAQ:INAB) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has stronger valuation & earnings, INAB or RLMD? Relmada Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$0.75-0.44Relmada TherapeuticsN/AN/A-$98.79M-$2.87-1.06 Do institutionals & insiders have more ownership in INAB or RLMD? 92.1% of IN8bio shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend INAB or RLMD? IN8bio currently has a consensus target price of $7.75, indicating a potential upside of 2,259.93%. Relmada Therapeutics has a consensus target price of $7.50, indicating a potential upside of 146.71%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Relmada Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor INAB or RLMD? In the previous week, IN8bio had 4 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for IN8bio and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.17 beat IN8bio's score of 0.48 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer INAB or RLMD? IN8bio received 7 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 72.73% of users gave IN8bio an outperform vote while only 41.46% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2472.73% Underperform Votes927.27% Relmada TherapeuticsOutperform Votes1741.46% Underperform Votes2458.54% Is INAB or RLMD more profitable? Relmada Therapeutics' return on equity of -129.80% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% Relmada Therapeutics N/A -129.80%-112.06% SummaryIN8bio beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.80M$3.09B$5.20B$8.97BDividend YieldN/A1.84%5.23%4.04%P/E Ratio-0.4415.2685.7113.39Price / SalesN/A315.091,469.4286.49Price / CashN/A175.8435.2935.09Price / Book0.574.044.914.96Net Income-$30.01M-$41.68M$117.36M$224.10M7 Day Performance5.94%6.57%2.75%2.01%1 Month Performance14.66%5.81%1.71%9.79%1 Year Performance-61.16%38.20%36.01%29.97% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.4139 of 5 stars$0.33-10.8%$7.75+2,259.9%-56.5%$23.80MN/A-0.4420Short Interest ↑Gap DownRLMDRelmada Therapeutics4.3808 of 5 stars$3.31+9.6%$7.50+126.6%+31.1%$99.88MN/A-1.1310Positive NewsANVSAnnovis Bio2.39 of 5 stars$7.20+7.3%$32.17+346.8%-14.3%$99.34MN/A-1.613ORMPOramed Pharmaceuticals1.8166 of 5 stars$2.46+3.8%N/A+15.7%$99.16M$1.34M21.5510Analyst DowngradeNews CoverageGNLXGenelux2.0525 of 5 stars$2.86+6.3%$18.25+538.1%-78.7%$98.78M$170,000.00-2.8310Positive NewsAVTXAvalo Therapeutics2.0836 of 5 stars$9.47-0.8%N/A-37.0%$98.43M$820,000.000.0040Positive NewsGap DownTLSATiziana Life Sciences0.6646 of 5 stars$0.93-2.3%N/A+58.8%$98.04MN/A0.008Positive NewsALGSAligos Therapeutics4.0687 of 5 stars$27.07+6.1%$75.00+177.1%+46.7%$97.13M$6.00M-1.9890News CoverageHigh Trading VolumeGNTAGenenta Science2.9295 of 5 stars$5.30+1.9%$25.00+371.7%+1.1%$96.94MN/A0.007Gap UpNVCTNuvectis Pharma3.3139 of 5 stars$5.00-0.8%$21.00+320.0%-41.5%$96.61MN/A-4.328Short Interest ↑ELYMEliem TherapeuticsN/A$3.23+0.3%N/A+24.9%$96.10MN/A-6.0920Positive News Related Companies and Tools Related Companies RLMD Competitors ANVS Competitors ORMP Competitors GNLX Competitors AVTX Competitors TLSA Competitors ALGS Competitors GNTA Competitors NVCT Competitors ELYM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INAB) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
